Literature DB >> 10752856

Combination therapy for pulmonary hypertension: a glimpse into the future?

R N Channick, L J Rubin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10752856     DOI： 10.1097/00003246-200003000-00055

Source DB:  PubMed          Journal:  Crit Care Med        ISSN： 0090-3493            Impact factor:   7.598


× No keyword cloud information.
  3 in total

1.  Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension.

Authors:  Fiona Murray; Margaret R MacLean; Nigel J Pyne
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

2.  An assessment of the role of the inhibitory gamma subunit of the retinal cyclic GMP phosphodiesterase and its effect on the p42/p44 mitogen-activated protein kinase pathway in animal and cellular models of pulmonary hypertension.

Authors:  Fiona Murray; Margaret R MacLean; Nigel J Pyne
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

Review 3.  Current management of primary pulmonary hypertension.

Authors:  E S Klings; H W Farber
Journal:  Drugs       Date:  2001       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.